GRO Biosciences

GRO Biosciences is leveraging groundbreaking science to expand the amino acid alphabet and fulfill the promise of protein therapeutics. The company is transforming treatment across multiple fields, including autoimmune and metabolic diseases, to improve patients' lives. GRObio is applying its platform to advance collaborative projects as well as its own pipeline of protein therapeutics, which feature unique NSAA (non-standard amino acid) chemistry. The company’s NSAA therapeutics possess previously unattainable capabilities, including unprecedented duration of action and precise modulation of the immune system. GRObio’s mission is to harness the unprecedented capabilities of NSAAs within the GRO platform to overcome long-standing limitations of protein therapeutics and deliver better health outcomes for patients. GRObio was co-founded in 2016 by Dr. George Church of Harvard Medical School and is headquartered in Cambridge, Massachusetts.